# Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

> **NCT06400368** · — · RECRUITING · sponsor: **NeuroVision Imaging** · enrollment: 200 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06400368
- **Lead sponsor:** NeuroVision Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-24
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06400368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06400368, "Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06400368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*